Euclidean Technologies Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Euclidean Technologies Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$216K	Buy	+263	New	+$198K	0.2%	66

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Euclidean Technologies Management's REGN Position: Q1 2023 in Review

Euclidean Technologies Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2023: 263 shares worth $216K. The stake represents 0.2% of the portfolio and ranks #66 among its holdings.

1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Euclidean Technologies Management held 263 shares of Regeneron Pharmaceuticals worth $216K as of Q1 2023.
Regeneron Pharmaceuticals was a new Euclidean Technologies Management position in Q1 2023.
Regeneron Pharmaceuticals made up 0.2% of Euclidean Technologies Management's portfolio in Q1 2023, its #66 holding.
1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Euclidean Technologies Management's 13F filing for Q1 2023, filed 26 Apr 2023.